XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (DEFICIT) - USD ($)
$ in Millions
Total
Bausch Health Companies Inc. Shareholders’ Deficit
Common Shares
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Non- controlling Interest
Beginning Balance (in shares) at Dec. 31, 2023     365,200,000        
Beginning Balance at Dec. 31, 2023 $ (82) $ (1,022) $ 10,423 $ 214 $ (9,778) $ (1,881) $ 940
Increase (Decrease) in Shareholders' Equity              
Common shares issued under share-based compensation plans (in shares)     2,500,000        
Common shares issued under share-based compensation plans 0   $ 66 (66)      
Share-based compensation 107 107   107      
Employee withholding taxes related to share-based awards (23) (23)   (23)      
Vesting of B+L equity compensation 0 (31)   (31)     31
Noncontrolling interest distributions (10)           (10)
Net income (170) (139)     (139)   (31)
Other comprehensive (loss) income (64) (66)       (66) 2
Ending Balance (in shares) at Sep. 30, 2024     367,700,000        
Ending Balance at Sep. 30, 2024 (242) (1,174) $ 10,489 201 (9,917) (1,947) 932
Beginning Balance (in shares) at Jun. 30, 2024     367,000,000.0        
Beginning Balance at Jun. 30, 2024 (227) (1,175) $ 10,483 181 (9,832) (2,007) 948
Increase (Decrease) in Shareholders' Equity              
Common shares issued under share-based compensation plans (in shares)     700,000        
Common shares issued under share-based compensation plans 0   $ 6 (6)      
Share-based compensation 38 38   38      
Employee withholding taxes related to share-based awards (5) (5)   (5)      
Vesting of B+L equity compensation 0 (7)   (7)     7
Noncontrolling interest distributions (10)           (10)
Net income (92) (85)     (85)   (7)
Other comprehensive (loss) income 54 60       60 (6)
Ending Balance (in shares) at Sep. 30, 2024     367,700,000        
Ending Balance at Sep. 30, 2024 $ (242) (1,174) $ 10,489 201 (9,917) (1,947) 932
Beginning Balance (in shares) at Dec. 31, 2024 367,843,058   367,800,000        
Beginning Balance at Dec. 31, 2024 $ (322) (1,279) $ 10,490 234 (9,824) (2,179) 957
Increase (Decrease) in Shareholders' Equity              
Common shares issued under share-based compensation plans (in shares)     2,700,000        
Common shares issued under share-based compensation plans 0   $ 25 (25)      
Share-based compensation 132 132   132      
Employee withholding taxes related to share-based awards (24) (24)   (24)      
Vesting of B+L equity compensation 0 (42)   (42)     42
Noncontrolling interest distributions (9)           (9)
Net income 223 269     269   (46)
Other comprehensive (loss) income $ 356 379       379 (23)
Ending Balance (in shares) at Sep. 30, 2025 370,473,221   370,500,000        
Ending Balance at Sep. 30, 2025 $ 356 (565) $ 10,515 275 (9,555) (1,800) 921
Beginning Balance (in shares) at Jun. 30, 2025     369,700,000        
Beginning Balance at Jun. 30, 2025 147 (764) $ 10,510 250 (9,734) (1,790) 911
Increase (Decrease) in Shareholders' Equity              
Common shares issued under share-based compensation plans (in shares)     800,000        
Common shares issued under share-based compensation plans 0   $ 5 (5)      
Share-based compensation 43 43   43      
Employee withholding taxes related to share-based awards (5) (5)   (5)      
Vesting of B+L equity compensation 0 (8)   (8)     8
Noncontrolling interest distributions 0           0
Net income 181 179     179   2
Other comprehensive (loss) income $ (10) (10)       (10) 0
Ending Balance (in shares) at Sep. 30, 2025 370,473,221   370,500,000        
Ending Balance at Sep. 30, 2025 $ 356 $ (565) $ 10,515 $ 275 $ (9,555) $ (1,800) $ 921